As Reported by the Senate Health Committee

136th General Assembly

Regular Session **Sub. H. B. No. 324**

2025-2026

Representatives Mathews, A., Craig

Cosponsors: Representatives Schmidt, Gross, King, Miller, M., Stewart, Barhorst, Bird, Click, Dovilla, Fowler Arthur, Hall, T., John, Mathews, T., McClain, Newman, Odioso, Richardson, Salvo, Thomas, D., Williams, Young

Senators Romanchuk, Manchester, Johnson, Roegner, Huffman

To enact section 3715.39 of the Revised Code to establish conditions on the prescribing of drugs subject to a federal risk evaluation and mitigation strategy and to name this act the Patient Protection Act.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That section 3715.39 of the Revised Code be enacted to read as follows:

Sec. 3715.39. (A) As used in this section, "prescriber" has the same meaning as in section 4729.01 of the Revised Code, except that a prescriber does not include a veterinarian licensed under Chapter 4741. of the Revised Code.

(B) Before a prescriber may issue a prescription for a drug for which the United States food and drug administration requires a risk evaluation and mitigation strategy under section 355-1 of the "Federal Food, Drug, and Cosmetic Act," 21 U.S.C. 355-1, the prescriber shall do all of the following:

(1) Conduct an in-person examination of the patient;

(2) Inform the patient that the drug is subject to a risk evaluation and mitigation strategy, which may include guidelines or requirements for the patient's use of the drug;

(3) Schedule the patient for a follow-up appointment.

Section 2. This act shall be known as the Patient Protection Act.